O24 - Mite allergy prevention study by Zaraquiza Zolkipli et al.
ORAL PRESENTATION Open Access
O24 - Mite allergy prevention study
Zaraquiza Zolkipli1*, Graham Roberts2, Ramesh Kurukulaaratchy3, Louise J Michaelis4, Sharon Matthews3,
Catherine B Clayton3, Sarah Pearson1, Victoria Cornelius5, Syed Hasan Arshad2
From 3rd Pediatric Allergy and Asthma Meeting (PAAM)
Athens, Greece. 17-19 October 2013
Background
Infants with family history of atopy are considered at
high risk for developing allergic disease. Environmental
exposures are modifiable risk factors with a potential for
intervention to prevent allergy. Children who develop
house dust mite (HDM) sensitisation by pre-school age
are at higher risk of developing asthma. Prevention of
HDM sensitisation in early childhood by immune mod-
ulation may consequently prevent development of
asthma. We sought to achieve this by inducing tolerance
to HDM through high dose allergen exposure.
Aim
We aim to provide preliminary evidence of efficacy and
safety of sublingual immunotherapy with HDM in redu-
cing the development of atopy among infants of high-risk
families.
Methodology
We conducted a randomised, double-blind, placebo-con-
trolled trial over 2 sites: Southampton and the Isle of
Wight. Infants at high risk (at least 2 first-degree relatives
with atopy) were recruited at 5-6 months of age and
remained on the intervention for 12 months. Exclusion
criteria were skin prick test (SPT) positivity to screening
food and aeroallergens, prematurity and concurrent major
health problems. Participants underwent clinical and
immunological assessments at baseline. The intervention
was sublingual immunotherapy of either house dust mite
extract or saline (ALK-Abello, Denmark). Assessment,
including SPT was performed every 3 months to monitor
development of allergic symptoms and SPT positivity
(atopic sensitisation).
Results
We recruited a total of 111 participants. At baseline 42%
had objective evidence of eczema, 29% had parental report
of wheeze and 20% had parental report of food allergy. To
date, 66 infants have completed the study. Of these, 14
showed atopic sensitisation to at least 1 allergen (cumula-
tive rate 21%). There have been no adverse reactions
directly related to the interventional product.
Conclusion
We have demonstrated the safety of sublingual immu-
notherapy using HDM in high-risk infants with a cumu-
lative rate of atopic sensitisation of 21% over 12 months.
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